Antibe Therapeutics Inc. (OTCMKTS:ATBPF) Short Interest Down 73.1% in March

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) was the target of a significant drop in short interest in March. As of March 15th, there was short interest totalling 8,900 shares, a drop of 73.1% from the February 29th total of 33,100 shares. Based on an average trading volume of 88,700 shares, the short-interest ratio is presently 0.1 days.

Antibe Therapeutics Trading Down 1.6 %

Shares of OTCMKTS:ATBPF opened at $0.32 on Thursday. The firm has a market cap of $16.85 million, a price-to-earnings ratio of -1.27 and a beta of 0.57. The business has a fifty day simple moving average of $0.58 and a 200 day simple moving average of $0.55. Antibe Therapeutics has a 1 year low of $0.24 and a 1 year high of $0.89.

Antibe Therapeutics (OTCMKTS:ATBPF) last posted its earnings results on Wednesday, February 14th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.03. On average, sell-side analysts forecast that Antibe Therapeutics will post -0.3 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Brookline Capital Management lowered shares of Antibe Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, March 4th.

Antibe Therapeutics Company Profile

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).